Literature DB >> 10491418

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

G M Ortiz1, D F Nixon, A Trkola, J Binley, X Jin, S Bonhoeffer, P J Kuebler, S M Donahoe, M A Demoitie, W M Kakimoto, T Ketas, B Clas, J J Heymann, L Zhang, Y Cao, A Hurley, J P Moore, D D Ho, M Markowitz.   

Abstract

Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex drug regimens can prove problematic, and subjects may temporarily discontinue HAART for variable periods. We studied 6 HIV-1-infected individuals who stopped therapy. Off HAART, levels of viremia were suppressed to fewer than 500 copies/mL in 2 subjects for more than 12 and more than 24 months, respectively, and in 1 subject for 4 months on 1 occasion. Three subjects failed to contain plasma viremia. Broad and strong HIV-1-specific immune responses were detected in subjects with prolonged suppression of viral replication. This longitudinal study suggests that containment of HIV-1 replication to low or undetectable levels after discontinuation of HAART is associated with strong virus-specific immune responses. Boosting of HIV-1-specific immune responses should be considered as an adjunctive treatment strategy for HIV-1-infected individuals on HAART.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491418      PMCID: PMC408442          DOI: 10.1172/JCI7371

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.

Authors:  T R O'Brien; W A Blattner; D Waters; E Eyster; M W Hilgartner; A R Cohen; N Luban; A Hatzakis; L M Aledort; P S Rosenberg; W J Miley; B L Kroner; J J Goedert
Journal:  JAMA       Date:  1996-07-10       Impact factor: 56.272

2.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.

Authors:  J Vila; F Nugier; G Barguès; T Vallet; D Peyramond; F Hamedi-Sangsari; J M Seigneurin
Journal:  Lancet       Date:  1997-08-30       Impact factor: 79.321

4.  Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.

Authors:  M Purtscher; A Trkola; A Grassauer; P M Schulz; A Klima; S Döpper; G Gruber; A Buchacher; T Muster; H Katinger
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

5.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.

Authors:  D A Price; P J Goulder; P Klenerman; A K Sewell; P J Easterbrook; M Troop; C R Bangham; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

6.  Characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

9.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  48 in total

1.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Authors:  M Dalod; M Dupuis; J C Deschemin; C Goujard; C Deveau; L Meyer; N Ngo; C Rouzioux; J G Guillet; J F Delfraissy; M Sinet; A Venet
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

3.  Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Authors:  T W Chun; J S Justement; S Moir; C W Hallahan; L A Ehler; S Liu; M McLaughlin; M Dybul; J M Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

4.  Cytotoxic T-lymphocyte memory, virus clearance and antigenic heterogeneity.

Authors:  D Wodarz
Journal:  Proc Biol Sci       Date:  2001-02-22       Impact factor: 5.349

Review 5.  A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment.

Authors:  D Wodarz; K M Page; R A Arnaout; A R Thomsen; J D Lifson; M A Nowak
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

6.  HIV therapy: managing resistance.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

7.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

8.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

9.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

10.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.